342623-34-1

Basic information

• Product Name: methyl 4-chloro-2-isothiocyanatobenzoate
• Synonyms: methyl 4-chloro-2-isothiocyanatobenzoate
• CAS NO: 342623-34-1
• Molecular Weight: 227.671
• Mol File: 342623-34-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: methyl 4-chloro-2-isothiocyanatobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-chloro-2-isothiocyanatobenzoate(342623-34-1)
• EPA Substance Registry System: methyl 4-chloro-2-isothiocyanatobenzoate(342623-34-1)

Safety Data

• Hazardous Substances Data: 342623-34-1(Hazardous Substances Data)

Upstream product

• 5900-58-3 2-amino-4-chloro-benzoic acid methyl ester 
• 463-71-8 thiophosgene 

Downstream Products

• 19407-66-0 7-chloro-2-(4-methoxyphenyl)quinazolin-4(3H)-one 
• 33017-86-6 7-chloro-2-thioxo-2,3-dihydroquinazolin-4(1H)-one 
• 955954-39-9 2-(2-carbamoyl-2-cyano-thioacetylamino)-4-chloro-benzoic acid methyl ester 

Relevant articles and documents

Conversion of 2-thioxo-2,3-dihydroquinazolin-4(1H)-ones to N(3)-unsubstituted 2-(het)arylquinazolin-4(3H)-ones by copper-mediated Pd-catalysed cross-coupling reactions

With the purpose of searching for new heterocyclic building blocks, a new method to access N(3)-unsubstituted 2-(het)arylquinazolin-4(3H)-ones from 2-thioxo-2,3-dihydroquinazolin-4(1H)-one derivatives was developed. The synthetic protocol was based on the copper-mediated palladium-catalysed cross-coupling reactions of 2-thioxo-2,3-dihydroquinazolin-4(1H)-ones with (het)arylstannanes or their S-benzylated derivatives with (het)arylboronic acids, using CuBr·Me2S and CuMeSal as promoters, respectively. A similar transformation was applied for the preparation of 2-aryl[1]benzothieno[3,2-d]pyrimidin-4(3H)-ones.

Pyrimido-Benzimidazole Derivatives and the Use Thereof in the Form of Agonists and Antagonists of Melanocortin Receptors

The invention relates to novel pyrimido-benzimidazole derivatives. Said products exhibit a good affinity for certain melanocortin receptor sub-types, in particular MC4 receptors. Said products represent a particular interest for treating pathological disorders and diseases associated with one or several melanocortin receptors. Pharmaceutical compositions containing said products and the use thereof for a drug preparation are also disclosed.